Monday 27th July 2009
Syngene, a world-leading manufacturer of image analysis solutions, is pleased to announce the first ChromaScan automated non-radioactive TLC plate reader is being used in the main manufacturing facility of a major pharmaceutical company, to improve the accuracy of its drug testing.
The manufacturing plant in the UK is responsible for the worldwide supply of a range of therapies and is using the ChromaScan system to automatically image fluorescent and visible TLC plates to test samples for purity, stability and content uniformity. The samples tested include treatments for hypertension, arthritis and epilepsy, as well as the raw materials used in the manufacture of these drugs. Using an automated system is helping to ensure the results are both reproducible and more accurate, which will in turn assure the content of each batch of drugs is safer.
The ChromaScan installed in this pharma company is designed to increase throughput. For this, the system features full process automation with a computer controlled darkroom and camera. Since the ChromaScan was purchased with detailed Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ) procedures, it has allowed staff in the pharma company to rapidly install and validate the system’s performance on site so ChromaScan can now be confidently used in a GMP (Good Manufacturing Practice) environment.
Laura Sullivan, Syngene’s Divisional Manager commented: “We are delighted our ChromaScan system has been assessed so positively and is now being routinely used in one of the best pharmaceutical manufacturing facilities in the world. Their confidence in our new TLC plate reader’s performance is a great endorsement because it shows scientists wanting to automate TLC analysis in a quality driven environment that ChromaScan is a perfect choice.”
Copyright © 2009-2016 Syngene, A Division of Synoptics Ltd